Русский
Peculiarities of chronic kidney disease progression in the long-term period in multifocal atherosclerosis patients
DOI: https://dx.doi.org/10.18565/therapy.2022.6.34-40
Kobzeva N.D., Martynov A.I., Terentiev V.P., Batyushin M.M.
1) Rostov State Medical University of the Ministry of Healthcare of Russia, Rostov-on-Don; 2) A.I. Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia
The aim is to study the peculiarities of CKD progression and develop an algorithm for its prediction in patients with multifocal atherosclerosis.
Material and methods. The study included 519 patients with atherosclerotic lesions of different vascular basins treated in profile departments. 360 (69,4%) of them were males and 159 (30,6%) – females. Average age of the examined patients was 60,0±8,7 years old. The patients underwent a complex of laboratory and a number of instrumental examinations, including (if indicated) coronary angiography, angiography of renal, brachiocephalic and lower limb arteries. During the prospective follow-up (36 months) the peculiarities of CKD progression in the presented group of patients were evaluated.
Results. Data obtained by two-factor logistic regression analysis show a significant impact of such features as «GFR (CKD-EPI), ml/min/1,73m2 + nephrosclerosis», «presence of atherosclerotic lesion of posterior interventricular branch + degree of atherosclerotic stenosis of left renal artery in bilateral lesion, %» on risk of CKD development in long-term follow-up period of the study group patients.
Conclusion. The performed complex analysis made it possible to develop original nomograms of CKD risk assessment in the long-term period; their use in clinical practice will contribute to the identification of risk groups and increase the preventive measures efficacy in multifocal atherosclerosis patients.
Literature
1. Yang C.W., Harris D.C.H., Luyckx V.A. et al. Global case studies for chronic kidney disease/end-stage kidney disease care. Kidney Int Suppl. 2020; 10(1): e24–e48. https://dx.doi.org/10.1016/j.kisu.2019.11.010. 2. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020; 395(10225): 709–33.https://dx.doi.org/10.1016/S0140-6736(20)30045-3. 3. Tao W.W., Tao X.M., Wang Y., Bi S.H. Psycho-social and educational interventions for enhancing adherence to dialysis in adults with end-stage renal disease: A meta- analysis. J Clin Nurs. 2020; 29(15–16): 2834–48. https://dx.doi.org/10.1111/jocn.15301 4. Ding L., Yang J., Li L., Yang Y. Effects of ACEIs and ARBs on the residual renal function in peritoneal dialysis patients: A meta-analysis of randomized controlled trials. Biomed Res Int. 2020; 2020: 6762029. https://dx.doi.org/10.1155/2020/6762029. 5. Sridharan K., Sivaramakrishnan G. Drug therapies for patients with IgA nephropathy: A network meta-analysis of randomized clinical trials. Curr Clin Pharmacol. 2020; 15(2): 132–44. https://dx.doi.org/10.2174/1574884715666191223103914. 6. Zhang D., Ding Y., Wang X. et al. Effects of ABCG2 and SLCO1B1 gene variants on inflammation markers in patients with hypercholesterolemia and diabetes mellitus treated with rosuvastatin. Eur J Clin Pharmacol. 2020; 76(7): 939–46.https://dx.doi.org/10.1007/s00228-020-02882-4. 7. Major R.W., Cheng M.R.I., Grant R.A. et al. Cardiovascular disease risk factors in chronic kidney disease: A systematic review and meta-analysis. PLoS One. 2018; 13(3): e0192895. https://dx.doi.org/10.1371/journal.pone.0192895. 8. Williams B., Mancia G., Spiering W. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39(33): 3021–104. https://dx.doi.org/10.1093/eurheartj/ehy339. 9. Hill N.R., Fatoba S.T., Oke J.L. et al. Global prevalence of chronic kidney disease – a systematic review and meta-analysis. PLoS One. 2016; 11(7): e0158765. https://dx.doi.org/10.1371/journal.pone.0158765. 10. Kumbhani D.J., Steg P.G., Cannon C.P. et al.; REACH Registry Investigators. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: Insights from the REACH registry. Eur Heart J. 2014; 35(41): 2864–72.https://dx.doi.org/10.1093/eurheartj/ehu080. 11. Fenstad E.R., Kane G.C. Update on the management of atherosclerotic renal artery disease. Minerva Cardioangiol. 2009; 57(1): 95–101. 12. Hagemann R., Silva Vdos S., Franco R.J. et al. [Effect of renal revascularization on the development of renal dysfunction in atherosclerotic ischemic nephropathy. J Bras Nefrol. 2014; 36(4): 535–41 (Article in English, Portuguese)].https://dx.doi.org/10.5935/0101-2800.20140076. 13. Chrysant S.G. The current status of angioplasty of atherosclerotic renal artery stenosis for the treatment of hypertension. J Clin Hypertens (Greenwich). 2013; 15(9): 694–98. https://dx.doi.org/10.1111/jch.12161. 14. Inker L.A., Heerspink H.J.L., Tighiouart H. et al. GFR slope as a surrogate end point for kidney disease progression in clinical trials: A meta-analysis of treatment effects of randomized controlled trials. J Am Soc Nephrol. 2019; 30(9): 1735–45.https://dx.doi.org/10.1681/ASN.2019010007. 15. Yarnoff B.O., Hoerger T.J., Simpson S.K. et al. The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease. BMC Nephrol. 2017; 18(1):85. https://dx.doi.org/10.1186/s12882-017-0497-6. 16. Ashby D., Borman N., Burton J. et al. Renal association clinical practice guideline on haemodialysis. BMC Nephrol. 2019; 20(1): 379. https://dx.doi.org/10.1186/s12882-019-1527-3.
About the Autors
Natalia D. Kobzeva, PhD in Medicine, associate professor of the Department of internal diseases No. 1, Rostov State Medical University of the Ministry of Healthcare of Russia. Address: 344022, Rostov-on-Don, 29 Nakhichevansky Lane. E-mail: kobzeva.nataliya1@gmail.com. ORCID: https://orcid.org/0000-0002-3390-2452
Anatoly I. Martynov, Dr. med. habil., professor, academician of RAS, professor of the Department of hospital therapy No. 1, A.I. Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia. Address: 127473, Moscow, 20/1 Delegatskaya Str. ORCID: https://orcid.org/0000-0002-0783-488X
Vladimir P. Terentiev, Dr. med. habil., professor, head of the Department of internal diseases No. 1, Rostov State Medical University of the Ministry of Healthcare of Russia. Address: 344022, Rostov-on-Don, 29 Nakhichevansky Lane. E-mail: vpterentev@mail.ru. ORCID: https://orcid.org/0000-0003-3607-5832
Mikhail M. Batyushin, Dr. med. habil., professor, professor of the Department of internal diseases No. 2, Rostov State Medical University of the Ministry of Healthcare of Russia. Address: 344022, Rostov-on-Don, 29 Nakhichevansky Lane. E-mail: batjushin-m@rambler.ru, ORCID: https://orcid.org/0000-0002-3032-7202
Similar Articles
